SCHEMBL6685508

SCHEMBL6685508

Nc1cc(N)c2cc(NCc3ccccc3)ncc2n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAP4K4 O95819 1/20 0.44
APP P05067 2/20 0.43
NOS2 P35228 1/20 0.43
NCF1 P14598 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
DHFR P00374 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
FABP1 P07148 1/20 0.42
FABP6 P51161 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469221 0.75 MEN1 (0.57) EGFRSMN1; SMN2ALDH1A1HPGDMAP4K4
SCHEMBL7173404 0.73 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1HPGDKDM4ENOS2
SCHEMBL12685852 0.73 HDAC3 (0.49) SMN1; SMN2ALDH1A1HPGDMAP4K4NOS2
SCHEMBL23609251 0.71 CYP1A2 (0.49) SMN1; SMN2ALDH1A1HPGDNOS2MEN1
SCHEMBL10005387 0.70 CYP2D6 (0.56) EGFRSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL27981294 0.68 HDAC1 (0.56) EGFR
SCHEMBL7231916 0.68 FABP1 (0.58) EGFRSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL13101047 0.67 FYN (0.59) SMN1; SMN2ALDH1A1HPGDMAP4K4APP
SCHEMBL7459147 0.67 NOS2 (0.66) EGFRSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL13256483 0.67 FABP1 (0.51) SMN1; SMN2ALDH1A1HPGDKDM4EMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004082613-A2 2,4-DIAMINO-5-[5’-SUBSTITUTED-BENZYL] PYRIMIDINES AND 2,4-DIAMINO-6-[5’-SUBSTITUTED-BENZYL] QUINAZOLINES DANA FARBER CANCER INSTITUTE (US) 2004-09-30 WO disclosed